PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro

References

• Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J.Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32. doi:10.3322/caac.21338. PMID:26808342.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. doi:10.3322/caac.21332. PMID:26742998.
   PubMed Web of Science ®Google Scholar
• Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, et al. .Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29:2904–9. doi:10.1200/JCO.2010.33.9275. PMID:21690468.
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, et al. .KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305:2327–34. doi:10.1001/jama.2011.746. PMID:21642685.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, et al. .Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809–19. doi:10.1056/NEJMoa1002011. PMID:20818844.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et al. .Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107–14. doi:10.1056/NEJMoa1203421. PMID:22663011.
   PubMed Web of Science ®Google Scholar
• Hay N, Sonenberg N .Upstream and downstream of mTOR. Genes Dev. 2004;18:1926–45. doi:10.1101/gad.1212704. PMID:15314020.
   PubMed Web of Science ®Google Scholar
• Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994;369:756–8. doi:10.1038/369756a0. PMID:8008069.
   PubMed Web of Science ®Google Scholar
• Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000;103:253–62. doi:10.1016/S0092-8674(00)00117-3. PMID:11057898.
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441:424–30. doi:10.1038/nature04869. PMID:16724053.
   PubMed Web of Science ®Google Scholar
• Dronca RS, Allred JB, Perez DG, Nevala WK, Lieser EA, Thompson M, Maples WJ, Creagan ET, Pockaj BA, Kaur JS, et al. .Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol. 2014;37:369–76. doi:10.1097/COC.0b013e31827b45d4. PMID:23357973.
   PubMed Web of Science ®Google Scholar
• Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, Gajewski T, Quirt I, Doroshow JH .CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer. 2005;104:1045–8. doi:10.1002/cncr.21265. PMID:16007689.
   PubMed Web of Science ®Google Scholar
• Rao RD WHE, Allred JB LVJ, Maples WJ GMK. Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma. J Clin Oncol. 2006;24(18_suppl):8043–43, Abs8043.
   Web of Science ®Google Scholar
• Niu B, Scott AD, Sengupta S, Bailey MH, Batra P, Ning J, Wyczalkowski MA, Liang WW, Zhang Q, McLellan MD, et al. .Protein-structure-guided discovery of functional mutations across 19 cancer types. Nat Genet. 2016;48:827–37. doi:10.1038/ng.3586. PMID:27294619.
   PubMed Web of Science ®Google Scholar
• Kong Y, Si L, Li Y, Wu X, Xu X, Dai J, Tang H, Ma M, Chi Z, Sheng X, et al. .Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors. Clin Cancer Res. 2016;22:1018–27. doi:10.1158/1078-0432.CCR-15-1110. PMID:26490311.
   PubMed Web of Science ®Google Scholar
• Sato T, Nakashima A, Guo L, Coffman K, Tamanoi F. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene. 2010;29:2746–52. doi:10.1038/onc.2010.28. PMID:20190810.
   PubMed Web of Science ®Google Scholar
• Cermak T, Doyle EL, Christian M, Wang L, Zhang Y, Schmidt C, Baller JA, Somia NV, Bogdanove AJ, Voytas DF. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 2011;39:e82. doi:10.1093/nar/gkr218. PMID:21493687.
   PubMed Web of Science ®Google Scholar
• Murugan AK, Alzahrani A, Xing M. Mutations in critical domains confer the human mTOR gene strong tumorigenicity. J Biol Chem. 2013;288:6511–21. doi:10.1074/jbc.M112.399485. PMID:23322780.
   PubMed Web of Science ®Google Scholar
• Tee AR, Blenis J, Proud CG. Analysis of mTOR signaling by the small G-proteins, Rheb and RhebL1. FEBS Lett. 2005;579:4763–8. doi:10.1016/j.febslet.2005.07.054. PMID:16098514.
   PubMed Web of Science ®Google Scholar
• Sekulić A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM, Abraham RT. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 2000;60:3504–13. PMID:10910062.
   PubMed Web of Science ®Google Scholar
• Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, Stokoe D, McCormick F, Feng J, Tsichlis P. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 1998;17:313–25. doi:10.1038/sj.onc.1201947. PMID:9690513.
   PubMed Web of Science ®Google Scholar
• Strickland LR, Pal HC, Elmets CA, Afaq F. Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Lett. 2015;359:20–35. doi:10.1016/j.canlet.2015.01.016. PMID:25597784.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT01960829?term=NCT01960829&rank=1.
   Google Scholar
• Kurdi A, De Doncker M, Leloup A, Neels H, Timmermans JP, Lemmens K, Apers S, De Meyer GRY, Martinet W. Continuous administration of the mTORC1 inhibitor everolimus induces tolerance and decreases autophagy in mice. Br J Pharmacol. 2016;173:3359–71. doi:10.1111/bph.13626. PMID:27638766.
   PubMed Web of Science ®Google Scholar
• Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, Li J, Gao B, Ji Q, Maynard J, et al. .Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012;11:873–87. doi:10.1158/1535-7163.MCT-11-0824-T. PMID:22294718.
   PubMed Web of Science ®Google Scholar
• Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res. 2000;6:880–6. PMID:10741711.
   PubMed Web of Science ®Google Scholar
• Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, et al. .MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9:1956–67. doi:10.1158/1535-7163.MCT-09-1012. PMID:20571069.
   PubMed Web of Science ®Google Scholar
• Ng SS, Tsao MS, Nicklee T, Hedley DW. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res. 2001;7:3269–75. PMID:11595724.
   PubMed Web of Science ®Google Scholar